Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Associates Midwest LLC

Neither a doctor nor a teaching hospital

Research payments

$120,616

23 payments

Through program year 2025, Clinical Associates Midwest LLC is reported as receiving $120,616 in research payments, across 23 payments.

By program year

2 rows
Year Kind Amount Payments
2025 Research $80,294 16
2024 Research $40,322 7

Breakdown

Who paid Research payments · program years 2024–2025
  1. Pfizer Inc. $59,946 10 payments
  2. AbbVie, Inc. $36,089 10 payments
  3. Ironwood Pharmaceuticals, Inc $24,581 3 payments
Studies the money was for Research payments · program years 2024–2025
  1. Phase 3 Multicenter Randomized Doubleblind Group Sequential Placebocontrolled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $53,157 8 payments
  2. C3300-201 $24,581 3 payments
  3. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $15,700 4 payments
  4. Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $12,640 3 payments
  5. Phase 3 Multicenter Openlabel Study to Assess the Longterm Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $6,790 2 payments
  6. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $5,953 1 payment
  7. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) $1,430 1 payment
  8. Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $366 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record